Flu virus readily gains resistance to current and new antivirals
Pandemics are an inevitable feature of influenza virus. Current antivirals work by directly targeting influenza virus proteins, such as viral neuraminidase and polymerase, and are highly vulnerable to resistance development due to mutations.
In such eventualities, both seasonal vaccines and existing antivirals are of limited value. Thus, there is the unmet need for antivirals to be more effective and resistant to viral mutations.
This technology developed at the University of Nottingham comprises a small molecule that stimulates a highly effective host antiviral response against influenza virus and respiratory syncytial virus (RSV) which includes interference of viral protein transport and assembly, and enhanced type I and III interferon response. The compound can be orally administered, and is difficult for virus to overcome by mutation.
